GNB2

GNB2 encodes the β2 subunit of heterotrimeric G-proteins, functioning as a core signal transduction component that partners with Gγ subunits to relay GPCR-initiated signals through multiple downstream effector pathways. Gain-of-function mutations at the Gα-binding interface (e.g., p.Arg52Leu) cause sustained activation of GIRK potassium channels underlying familial sinus node dysfunction, while somatic (p.Lys78Glu) and germline loss-of-function variants at the same interface dysregulate Hippo/YAP and MAPK signalling in Sturge–Weber syndrome or cause a neurodevelopmental disorder with intellectual disability (PMID:28219978, PMID:34124757, PMID:34183358). In cancer contexts, GNB2 suppresses ferroptosis through physical interaction with HSPA5 and upregulation of GPX4, and its downregulation by miR-142-3p activates AKT–mTOR signalling to inhibit autophagy and reduce paclitaxel resistance (PMID:41240217, PMID:36539001). GNB2 also serves as a direct protein-binding partner of the lncRNA SNHG5, through which it activates Wnt/β-catenin signalling to promote epithelial–mesenchymal transition and colorectal cancer metastasis (PMID:41550840).

1. 1991 High

   Molecular identity of GNB2 was established by cloning the gene encoding the human Gβ2 subunit and mapping it to chromosome 7, providing the foundation for all subsequent functional studies of this G-protein component.

   Evidence Direct selection cDNA cloning from fetal kidney library hybridized to YAC, DNA sequencing and genomic mapping

   PMID:1946378

   Open questions at the time

   • No functional characterization of the encoded protein was performed
   • Tissue-specific expression pattern not addressed
2. 2016 Medium

   The first evidence that GNB2 has a pro-apoptotic role independent of canonical GPCR signalling came from showing that GNB2 upregulation is required for lidocaine-induced neuronal apoptosis.

   Evidence 2-DE/LC-MS/MS proteomics, qRT-PCR, siRNA knockdown with MTT and flow cytometry readouts in PC12 cells

   PMID:27018092

   Open questions at the time

   • Downstream signalling pathway linking GNB2 to apoptosis not identified
   • Relevance beyond lidocaine toxicity model unclear
   • No in vivo validation
3. 2017 High

   The first disease mechanism for GNB2 was defined: the p.Arg52Leu mutation causes sustained GIRK channel activation leading to membrane hyperpolarization and reduced pacemaker activity, establishing how Gβ2 mutations at the Gα-binding interface produce familial sinus node dysfunction.

   Evidence Electrophysiology in HEK-293T cells and Xenopus oocytes, molecular dynamics simulation, genome-wide linkage and exome sequencing in affected family

   PMID:28219978

   Open questions at the time

   • Paradox of reduced GIRK binding yet sustained activation not fully resolved structurally
   • Selective effect on GIRK versus other Gβγ effectors not explained mechanistically
4. 2021 Medium

   The pathogenic repertoire of GNB2 mutations was expanded to two additional disorders — Sturge–Weber syndrome (somatic p.Lys78Glu) and a neurodevelopmental syndrome (germline variants at the Gα interface) — converging on the principle that disruption of the Gα–Gβ2 interaction produces continuous G-protein signalling with tissue-specific consequences including Hippo/YAP dysregulation.

   Evidence Deep sequencing of patient biopsies, ectopic expression in endothelial cells with Western blot for YAP/MAPK (SWS); exome sequencing of 12 unrelated individuals with in silico structural modelling (neurodevelopmental disorder)

   PMID:34124757 PMID:34183358

   Open questions at the time

   • Direct biochemical measurement of Gα–Gβ2 binding disruption not performed for any variant
   • Mechanism linking continuous Gβγ release to YAP reduction not delineated
   • Neurodevelopmental variants lack any cellular functional validation
5. 2022 Medium

   GNB2 was positioned as a signalling node in cancer drug resistance: miR-142-3p directly targets GNB2, and GNB2 suppression activates AKT–mTOR to inhibit autophagy, sensitizing breast cancer cells to paclitaxel.

   Evidence miRNA mimic/inhibitor and siRNA knockdown, luciferase reporter, Western blot for AKT/mTOR/autophagy markers, CCK-8 and flow cytometry in breast cancer cells

   PMID:36539001

   Open questions at the time

   • Whether GNB2 regulates AKT–mTOR as a Gβγ dimer or through a non-canonical mechanism is unknown
   • No in vivo chemosensitization data
6. 2025 Medium

   A direct physical interaction between GNB2 and the ER chaperone HSPA5 was demonstrated, placing GNB2 upstream of HSPA5/GPX4 in a ferroptosis-suppressive axis that promotes breast cancer proliferation and metastasis.

   Evidence Co-immunoprecipitation, functional rescue with HSPA5 restoration, in vivo xenograft and metastasis models

   PMID:41240217

   Open questions at the time

   • Reciprocal Co-IP and domain-mapping of the GNB2–HSPA5 interaction not shown
   • Whether this function depends on Gβγ dimer formation or is Gβ2-autonomous is unresolved
7. 2026 Medium

   GNB2 was identified as a direct RNA-binding partner of lncRNA SNHG5, through which it activates Wnt/β-catenin signalling and promotes EMT in colorectal cancer liver metastasis.

   Evidence Biotin-RNA pull-down with mass spectrometry, RIP, RNA-FISH, functional rescue in vitro and in vivo liver metastasis model

   PMID:41550840

   Open questions at the time

   • Binding domain on GNB2 for SNHG5 not mapped
   • Whether SNHG5 binding alters Gβ2 conformation or availability for Gα/Gγ is unknown
   • Single-lab finding awaiting independent replication

• A unified structural and biochemical framework explaining how GNB2 functions in both canonical Gβγ signalling and the emerging non-canonical roles (ferroptosis suppression, lncRNA-mediated Wnt activation, autophagy regulation) remains unestablished.
• No crystal structure of disease-associated GNB2 mutants exists
• Whether cancer-context functions require Gγ dimerization is untested
• Relative contribution of GNB2 versus other Gβ isoforms in each pathway is unknown